Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
290
Views
0
CrossRef citations to date
0
Altmetric
Letters to Editor

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

David A. Bonda Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyORCID Iconhttps://orcid.org/0000-0003-0773-1829
ORCID Icon,
Ying Huanga Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Beth A. Christiana Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Samantha Jaglowskia Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyORCID Iconhttps://orcid.org/0000-0002-4335-2554
ORCID Icon,
Don Bensona Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Lapo Alinaria Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Robert A. Baiocchia Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology
,
Jonathon B. Cohenb Emory University, Atlanta, GA, USA
,
Kristie A. Bluma Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology;b Emory University, Atlanta, GA, USA
&
Kami J. Maddocksa Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyCorrespondence[email protected]
 show all
Pages 1750-1753 | Received 19 May 2021, Accepted 22 Jan 2022, Published online: 06 Feb 2022

References

  • Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167(1):19–32.
  • Zang C, Eucker J, Liu H, et al. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(2):425–434.
  • Matas-Cespedes A, et al. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (buparlisib). Clin Cancer Res. 2014;20(13):3458–3471.
  • Serrat N, Guerrero-Hernández M, Matas-Céspedes A, et al. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax . Blood Adv. 2020;4(17):4217–4231.
  • Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188–2195.
  • Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–446.
  • Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99(3):1038–1043.
  • de Gooijer MC, Zhang P, Buil LCM, et al. Buparlisib is a brain penetrable pan-PI3K inhibitor. Sci Rep. 2018;8(1):10784.
  • Maira S-M, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–328.
  • Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–290.
  • Younes A, Salles G, Martinelli G, et al. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2017;102(12):2104–2112.
  • Andre F, et al. Alpelisib for PIK3CA-Mutated, hormone Receptor-Positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940.
  • Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905.
  • Assouline S, Amrein L, Aloyz R, et al. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2020;61(7):1653–1659.
  • Heudel P-E, Fabbro M, Roemer-Becuwe C, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br J Cancer. 2017;116(3):303–309.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.